Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy (MMPOWER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02367014
Recruitment Status : Completed
First Posted : February 20, 2015
Results First Posted : December 27, 2019
Last Update Posted : December 27, 2019
Sponsor:
Information provided by (Responsible Party):
Stealth BioTherapeutics Inc.

Brief Summary:
Phase 1/2, multi-center, randomized, double-blind, multiple ascending dose, placebo-controlled study that enrolled 36 subjects with mitochondrial myopathy associated with genetically confirmed mitochondrial disease to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MTP-131 in this patient population.

Condition or disease Intervention/treatment Phase
Mitochondrial Myopathy Drug: elamipretide (low dose) Drug: elamipretide (intermediate dose) Drug: elamipretide (high dose) Drug: Placebo Phase 1 Phase 2

Detailed Description:

This multi-center, randomized, double-blind, placebo-controlled study enrolled 36 subjects into 3 cohorts of 12 subjects each to evaluate treatment with 3 ascending doses of intravenous elamipretide (0.01, 0.10, and 0.25 mg/kg/hr infused for 2 hours). After each cohort, a Safety Monitoring Board (SMB) determined if dose escalation to the next higher dose of elamipretide was warranted. Each cohort went through 3 distinct periods: Screening, Treatment, and Follow-up.

The Screening Period started with informed consent and may have lasted up to 40 days. During this period, screening procedures to determine subject eligibility for the study occurred, including confirmation of disease, which incorporated a committee review of the investigator-submitted diagnosis and genetic results. The Treatment Period began on Day 1 (Visit 2) and lasted for 5 days (until Day 5 [Visit 6]). Within each cohort, 9 subjects were randomized to active drug and 3 subjects were randomized to placebo on Day 1 and subjects received treatment once a day for 5 consecutive days. Safety, tolerability, and efficacy measures were performed at pre-specified times. The Follow-up Period began at the time of discharge on Day 5. Subjects returned to the study center for the Follow-up Visit on Day 7 (+1 day).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 1/2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Clinical Study for the Safety, Tolerability, and Efficacy of IV MTP-131 for Mitochondrial Myopathy in Genetically Confirmed Mitochondrial Disease
Study Start Date : February 2015
Actual Primary Completion Date : April 2016
Actual Study Completion Date : April 2016


Arm Intervention/treatment
Experimental: Low Dose
elamipretide 0.01 mg/kg/hr infused for 2 hours for 5 days
Drug: elamipretide (low dose)
elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
Other Name: MTP-131

Experimental: Intermediate dose
elamipretide 0.10 mg/kg/hr infused for 2 hours for 5 days
Drug: elamipretide (intermediate dose)
elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
Other Name: MTP-131

Experimental: High dose
elamipretide 0.25 mg/kg/hr infused for 2 hours for 5 days
Drug: elamipretide (high dose)
elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
Other Name: MTP-131

Placebo Comparator: Placebo
In each cohort, subjects received either IV elamipretide given once daily for 2 hours for 5 days or matching placebo.
Drug: Placebo
placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days




Primary Outcome Measures :
  1. Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT) [ Time Frame: Assessed at Baseline, Day 5 (end-of-treatment visit) ]
    Change in distance walked as measured by meters on the 6-minute walk test from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).


Secondary Outcome Measures :
  1. Change in Maximum Oxygen Uptake (ml/kg/Min) [ Time Frame: Baseline, Day 5 ]
    Change in maximum oxygen uptake as measured by mL/kg/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  2. Change in Ventilatory Efficiency (VE/VCO2 Slope) [ Time Frame: Baseline, Day 5 ]
    Change in ventilatory efficiency as measured by the VE/VCO2 slope from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  3. Change in Aerobic Efficiency (ΔO2 Consumption/Δ Work Ratio) [ Time Frame: Baseline, Day 5 ]
    Change in aerobic efficiency as measured by ΔO2 consumption/Δ work ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  4. Change in Oxygen Utilization (ΔVO2/ΔlogVE Ratio) [ Time Frame: Baseline, Day 5 ]
    Change in oxygen utilization as measured by ΔVO2/ΔlogVE ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  5. Change in Oxygen Uptake Kinetics (Mean Response Time as Measured by Seconds) [ Time Frame: Baseline, Day 5 ]
    Change in oxygen uptake kinetics (mean response time) as measured by seconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  6. Change in Pre-exercise Lactate Levels (mg/dL) [ Time Frame: Baseline, Day 5 ]
    Change in pre-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  7. Change in Post-exercise Lactate Levels (mg/dL) [ Time Frame: Baseline, Day 5 ]
    Change in post-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  8. Change in Peak Respiratory Exchange Ratio (VCO2/VO2) [ Time Frame: Baseline, Day 5 ]
    Change in peak respiratory exchange ratio as measured by VCO2/VO2 from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  9. Change in Peak Respiratory Rate (Breaths/Min) [ Time Frame: Baseline, Day 5 ]
    Change in peak respiratory rate as measured by breaths/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  10. Change in Peak Ventilation (L/Min) [ Time Frame: Baseline, Day 5 ]
    Change in peak ventilation as measured by L/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  11. Change in Peak Heart Rate (Beats/Min) [ Time Frame: Baseline, Day 5 ]
    Change in peak heart rate as measured by beats per minute from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  12. Change in Peak Oxygen Saturation (% O2-saturated Hemoglobin) [ Time Frame: Baseline, Day 5 ]
    Change in peak oxygen saturation as measured by percentage of O2-saturated hemoglobin from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  13. Change in Peak Systolic Blood Pressure (mmHg) [ Time Frame: Baseline, Day 5 ]
    Change in peak systolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  14. Change in Peak Diastolic Blood Pressure (mmHg) [ Time Frame: Baseline, Day 5 ]
    Change in peak diastolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  15. Change in Peak Borg Dyspnea [ Time Frame: Baseline, Day 5 ]
    Change in peak Borg dyspnea as measured by 0-10 with 0 meaning no breathlessness and 10 meaning maximal breathlessness from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  16. Change in VO2 Anaerobic Threshold (mL) [ Time Frame: Baseline, Day 5 ]
    Change in VO2 anaerobic threshold as measured by mL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  17. Change in Watts [ Time Frame: Baseline, Day 5 ]
    Change in watts from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  18. Change in Temperature (°C) [ Time Frame: Baseline, Day 5 ]
    Change in temperature as measured by units of Celsius from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  19. Change in ECG-PR Interval (Msec) [ Time Frame: Baseline, Day 5 ]
    Change in PR interval as measured by ECG in milliseconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  20. Change in ECG-QRS Complex (Msec) [ Time Frame: Baseline, Day 5 ]
    Change in QRS complex as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  21. Change in ECG-QT Interval (Msec) [ Time Frame: Baseline, Day 5 ]
    Change in QT interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  22. Change in ECG-QTc Interval (Msec) [ Time Frame: Baseline, Day 5 ]
    Change in QTc interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  23. Number of Participants Who Had Suicide Ideation, Suicidal Behavior, or Non-suicidal Self-injurious Behavior Post-screening. [ Time Frame: Days 1-5 and Day 7. ]
    Number of participants with suicide ideation, suicidal behavior, or non-suicidal self-injurious behavior post-screening as measured on Days 1-5, and Day 7 on the Columbia Suicide Severity Rating Scale (CSSRS). A yes/no binary response is utilized in the following ten categories: 1 - Wish to be Dead; 2 - Non-specific Active Suicidal Thoughts; 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; 5 - Active Suicidal Ideation with Specific Plan and Intent; 6 - Preparatory Acts or Behavior; 7 - Aborted Attempt; 8 - Interrupted Attempt; Category 9 - Actual Attempt (non-fatal); 10 - Completed Suicide. A yes/no binary response is also utilized in assessing self-injurious behavior without suicidal intent. A lower score means a better outcome whereas a higher score means a worse outcome.

  24. Change in Creatine Phosphokinase (IU/L) [ Time Frame: Baseline, Day 5 ]
    Change in Creatine Phosphokinase as measured by IU/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  25. Change in Alanine Aminotransferase (ALT) (U/L) [ Time Frame: Baseline, Day 5 ]
    Change in Alanine aminotransferase (ALT) as measured by (U/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  26. Change in Aspartate Aminotransferase (AST) (U/L) [ Time Frame: Baseline, Day 5 ]
    Change in aspartate aminotransferase (AST) as measured by U/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

  27. Change in Eosinophils (10^9 Cells/L) [ Time Frame: Baseline, Day 5 ]
    Change in eosinophils as measured by (10^9 cells/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of mitochondrial disease believed to impair the mitochondrial respiratory chain.
  • Eligibility requires prior genetic confirmation of mitochondrial disease.
  • Diagnosis of mitochondrial myopathy judged by the Investigators to be due to existing mitochondrial disease.
  • Must be able to complete a Screening Visit 6MWT.
  • Body mass index (BMI) score >15.0 and <35.0 kg/m2 at Screening Visit.
  • Women of childbearing potential must agree to use birth control as specified in the protocol from the date they sign the ICF until two months after the last dose of study drug.

Exclusion Criteria:

  • Any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all study requirements.
  • Had any exclusionary Newcastle Mitochondrial Disease Adult Scale (NMDAS) scores at Screening Visit.
  • Hospitalized (admitted as in-patient) within 1 month prior to the Baseline Visit.
  • A history of type 1 diabetes mellitus (T1DM).
  • Uncontrolled Type 1 (T1DM) or Type 2 diabetes mellitus (T2DM), in the opinion of the investigator.
  • A creatinine clearance <45 mL/min as calculated by the Cockcroft Gault equation.
  • Requires pacemaker, defibrillator, or has undergone cardiac surgery within 2 years of Screening Visit.
  • QTc elongation defined as a QTc >450 msec in male subjects and >480 msec in female subjects.
  • Uncontrolled hypertension (>160 mmHg systolic or >100 mmHg diastolic) at Screening Visit.
  • History of rhabdomyolysis defined as an acute rise in the serum creatine phosphokinase (CPK) value that, in the opinion of the investigator, caused clinically significant symptoms.
  • Serum sodium more than 5 meq/L below the reference lower limit of normal at Screening Visit.
  • Participated in another interventional clinical trial within 3 months of the screening visit or is currently enrolled in a non-interventional clinical trial judged by the Investigator to be incompatible with the current trial.

    • Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02367014


Locations
Layout table for location information
United States, California
University of California
San Diego, California, United States, 92093
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Ohio
Akron Children's Hospital
Akron, Ohio, United States, 44308
United States, Pennsylvania
Children's Hospital of Pittsburg of UPMC
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Stealth BioTherapeutics Inc.
Layout table for additonal information
Responsible Party: Stealth BioTherapeutics Inc.
ClinicalTrials.gov Identifier: NCT02367014    
Other Study ID Numbers: SPIMM-201
First Posted: February 20, 2015    Key Record Dates
Results First Posted: December 27, 2019
Last Update Posted: December 27, 2019
Last Verified: December 2019
Keywords provided by Stealth BioTherapeutics Inc.:
Mitochondrial Myopathy
Primary Mitochondrial Disease
Bendavia™
elamipretide
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Diseases
Mitochondrial Myopathies
Mitochondrial Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Metabolic Diseases